Austin Retina Associates
Stephanie Collins, MBA has a diverse work experience. Stephanie started their career in 2000 at Austin Retina Associates, where they held various roles including Chief Executive Officer, Certified Ophthalmic Assistant, ROP Coordinator, and Patient Accounting. Stephanie'stenure at Austin Retina Associates lasted until 2014. In 2019, Stephanie joined the half Helen Foundation as the Past Board Chair.
Stephanie Collins, MBA, holds a Master of Business Administration (MBA) degree in Healthcare Administration, which they obtained from the University of Texas at Tyler in 2016. Prior to that, they completed their Bachelor of Business Administration (B.B.A.) degree in Business Administration and Management, General from Texas State University in the years 2005 to 2008.
This person is not in any teams
Austin Retina Associates
Austin Retina Associates has been serving the citizens of Austin and surrounding communities since 1978. It is the largest retinal specialty group in Central Texas. Each of the highly respected retina physicians at Austin Retina Associates is a board-certified, licensed ophthalmologist and fellowship-trained retinal surgeon who is an expert in managing diseases involving the retina, vitreous and macula. The Austin Retina specialists concentrate on diabetic eye disease, retinal detachment, macular edema, epiretinal membrane, floaters, retinal surgery and more. Between them is over 100 years of combined medical knowledge and professional experience in providing patients with the very best vitreoretinal care available. ARA continues to remain at the forefront of retinal specialty practices by utilizing cutting-edge diagnostic equipment while offering state-of-the-art surgical procedures and pharmaceutical treatment regimens. ARA collaborates with referring ophthalmologists, optometrists, primary care physicians and specialists to comprehensively treat vitreoretinal disease. Additionally, Austin Retina Associates is nationally recognized for its participation in ground-breaking, pivotal clinical trials for 25 years, which has allowed us to offer our patients the opportunity to receive novel procedures and therapies through enrollment in research studies.